BB Biotech AG held its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,229,428 shares of the biopharmaceutical company’s stock at the end of the first quarter. Alexion Pharmaceuticals accounts for approximately 4.9% of BB Biotech AG’s holdings, making the stock its 8th largest position. BB Biotech AG’s holdings in Alexion Pharmaceuticals were worth $149,056,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in ALXN. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in Alexion Pharmaceuticals by 0.4% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 12,855 shares of the biopharmaceutical company’s stock valued at $1,573,000 after buying an additional 47 shares during the last quarter. Grandfield & Dodd LLC raised its stake in Alexion Pharmaceuticals by 1.5% in the first quarter. Grandfield & Dodd LLC now owns 3,270 shares of the biopharmaceutical company’s stock valued at $396,000 after buying an additional 47 shares during the last quarter. Cim Investment Mangement Inc. raised its stake in Alexion Pharmaceuticals by 1.8% in the fourth quarter. Cim Investment Mangement Inc. now owns 5,433 shares of the biopharmaceutical company’s stock valued at $665,000 after buying an additional 94 shares during the last quarter. Bremer Trust National Association raised its stake in Alexion Pharmaceuticals by 1.7% in the first quarter. Bremer Trust National Association now owns 5,484 shares of the biopharmaceutical company’s stock valued at $665,000 after buying an additional 94 shares during the last quarter. Finally, Rathbone Brothers plc raised its stake in Alexion Pharmaceuticals by 5.3% in the first quarter. Rathbone Brothers plc now owns 1,990 shares of the biopharmaceutical company’s stock valued at $241,000 after buying an additional 100 shares during the last quarter. 94.98% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at 98.03 on Thursday. The firm has a 50-day moving average of $117.83 and a 200-day moving average of $123.64. The stock has a market capitalization of $22.01 billion, a price-to-earnings ratio of 46.70 and a beta of 1.39. Alexion Pharmaceuticals, Inc. has a 1-year low of $96.18 and a 1-year high of $157.02.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, April 27th. The biopharmaceutical company reported $1.38 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.33. The firm had revenue of $870 million for the quarter, compared to the consensus estimate of $826.63 million. Alexion Pharmaceuticals had a net margin of 12.46% and a return on equity of 10.58%. Alexion Pharmaceuticals’s quarterly revenue was up 24.3% compared to the same quarter last year. During the same period last year, the firm posted $1.11 EPS. Equities research analysts anticipate that Alexion Pharmaceuticals, Inc. will post $5.32 EPS for the current year.

WARNING: This report was first posted by Daily Political and is the property of of Daily Political. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://www.dailypolitical.com/2017/06/01/bb-biotech-ag-holds-position-in-alexion-pharmaceuticals-inc-alxn.html.

Several equities research analysts have recently issued reports on the stock. BMO Capital Markets reissued an “outperform” rating and set a $158.00 target price on shares of Alexion Pharmaceuticals in a research note on Wednesday, May 24th. Goldman Sachs Group Inc reissued a “buy” rating and set a $158.00 target price on shares of Alexion Pharmaceuticals in a research note on Wednesday, May 24th. Cowen and Company reissued a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Thursday, February 16th. Oppenheimer Holdings Inc. reissued a “hold” rating on shares of Alexion Pharmaceuticals in a research note on Tuesday, May 23rd. Finally, Barclays PLC reissued an “overweight” rating and set a $155.00 target price on shares of Alexion Pharmaceuticals in a research note on Wednesday, May 24th. Seven equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Alexion Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $164.49.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.